Brain & CNS Cancer
Brain and CNS cancers encompass a wide spectrum from low-grade gliomas to highly aggressive glioblastoma, meningiomas, medulloblastomas, and CNS metastases, each requiring distinct neuro-oncologic expertise. Molecular classification by WHO 2021 criteria using IDH, 1p/19q, MGMT, and TERT guides both prognosis and treatment. CancerFax helps patients access specialist neuro-oncology evaluation and advanced treatment programs globally.
- WHO 2021 molecular classification & IDH/MGMT status
- Targeted therapy, immunotherapy & radiation strategies
- Neuro-oncology specialist & clinical trial access
- Key Test
- Biopsy · Imaging · Molecular Panel
- Advanced Therapies
- Targeted Therapy · Immunotherapy
- Critical Factor
- Molecular profile · Stage at diagnosis
What is Brain & CNS Cancer
Types and Subtypes
Understanding the specific type and molecular subtype of brain & cns cancer is essential for determining the most appropriate treatment approach.
Symptoms and Signs
Symptoms of brain & cns cancer vary by stage and tumor location. Early-stage disease may be asymptomatic or cause only subtle symptoms.
Diagnosis and Staging
Definitive diagnosis requires tissue biopsy and comprehensive staging imaging. Molecular testing is essential for treatment planning.
Staging
Staging determines treatment intent and guides therapeutic decision-making.
Standard Treatment
Treatment is determined by histologic type, stage, molecular profile, and performance status.
Advanced & Emerging Therapies
The treatment landscape for advanced brain & cns cancer continues to evolve with new targeted agents and immunotherapy combinations.
Immunotherapy
Checkpoint Inhibitors
Pembrolizumab and nivolumab-based regimens have transformed recurrent/metastatic disease in eligible patients based on PD-L1 expression and molecular profile.
Targeted Therapy
Molecular-Guided Targeted Agents
Specific targeted agents are available for molecularly defined subgroups. Comprehensive NGS at diagnosis identifies eligible patients.
Biomarkers & Precision Medicine
Molecular biomarker testing is increasingly important for treatment selection in advanced disease.
When to Seek a Second Opinion
Specialist review is valuable at key decision points in management.
Clinical Trials & Research
Prognosis & Outcomes
Prognosis is stage- and molecular profile-dependent.
Supportive Care
Supportive care is integral to maintaining quality of life throughout treatment.
How CancerFax Helps You Explore Treatment Options
CancerFax supports brain tumor patients by reviewing pathology, molecular profile, MRI imaging, and WHO classification; coordinating specialist neuro-oncology second opinions; facilitating access to Tumor Treating Fields, temozolomide, bevacizumab, targeted agents for BRAF/IDH mutations, and clinical trials; and supporting patients exploring specialist neuro-oncology centers globally.
Get a free case reviewFrequently Asked Questions
Brain and central nervous system (CNS) tumors encompass a broad spectrum of malignancies arising from the brain parenchyma, meninges, spinal cord, and cranial nerves. Primary brain tumors — those arising in the CNS itself — are classified by the WHO CNS Tumor Classification (5th edition, 2021) based on histology, molecular profile, and integrated diagnosis.Glioblastoma (GBM, WHO grade 4) is the most common malignant primary brain tumor in adults, accounting for approximately 50% of all malignant... Treatment depends on stage and molecular profile. Contact CancerFax for specialist guidance.
A specialist second opinion is valuable when the diagnosis is complex, when molecular testing reveals actionable alterations, when treatment planning involves complex surgical or radiation decisions, or when disease has progressed and next-line options are being considered. Specialist centers may offer clinical trial access and treatment options not available locally.
Yes. CancerFax can assist by reviewing your medical reports, coordinating specialist second opinions, confirming molecular eligibility for targeted therapies and immunotherapy, and facilitating access to specialist centers and clinical trials globally including in China. Contact CancerFax to discuss your diagnosis and available options.